Clinical Trial

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Add-on dostarlimab to chemoradiation with etoposide and cisplatin and radiotherapy can improve progression-free survival (PFS) compared with historical controls who were treated with chemoradiation alone in SCNECC
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-02.
Trial Details
NCT Number NCT07336147
Lead Sponsor Chang Gung Memorial Hospital
Conditions Female
Enrollment 45 participants
Start Date 2025-12-22
Primary Completion 2027-12-22 (estimated)
Study Completion 2030-12-22 (estimated)
Updated on ClinicalTrials.gov 2026-01-14